Skip to main content
. 2019 Apr 25;2019(4):CD012663. doi: 10.1002/14651858.CD012663.pub2

Costa 2013.

Study characteristics
Patient sampling Aim of the study: to assess the value of MRI and MRI‐TBx added to standard SBx for detecting clinical relevant PCa
Type of study: retrospective analysis
Selection: retrospective selection of participants meeting inclusion criteria
Enrolled/eligible: 38/1053 (of the 1053 participants who had had an MRI, 38 participants met the inclusion criteria)
Inclusion period: August 2003‐August 2008
Patient characteristics and setting Inclusion criteria: men with ≥ 2 prior‐negative biopsies who underwent MRI and subsequent SBx complemented with MRI‐TBx of MRI‐suspicious lesions. All men were referred for MRI because of PSA > 4 ng/mL, PSA velocity > 0.75 ng/mL/year or equivocal histopathology from previous Bx
Setting: Boston, USA. University hospital
Age: mean 64 (range 48‐77)
PSA: mean 14.4 (range 1.8‐33.1)
Prostate volume: not reported
Index tests Index test 1 : MRI‐pathway: a 3 Tesla MRI machine (Genesis Signa LX Excite, GE Healthcare) was used, with T1, T2 and DCE sequences. An in‐house MRI Likert 1‐5 scale was used, grouping score 1‐3 negative and 4‐5 positive. Cognitive MRI‐TBx from MRI‐positive lesions were taken, depending on judgement of urologist
Index test 2: transrectal SBx was performed. Sequence of tests and number of cores were dependent on judgement of urologist. A total median of 19 (range 8‐28) cores (MRI‐TBx + SBx) were taken. MRI results were known at time of SBx performance
Target condition and reference standard(s) No reference standard is used in this agreement analyses study (MRI‐pathway vs SBx), therefore the reference standard domain is not applicable and disregarded.
Flow and timing All participants underwent the same type of tests. All participants were included in the analysis
Comparative  
Notes  
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Did the study avoid inappropriate exclusions? Yes    
    High Low
DOMAIN 2: Index Test SBx
Was the MRI assessed without knowledge of the results of the (reference or other index) biopsies? No    
Were the MRI‐TBx performed independent of the (reference or other index) biopsies?      
Was the performance of the SBx not influenced by the performance of the (reference or other index) biopsies?      
    High High
DOMAIN 2: Index Test MRI‐pathway
Was the MRI assessed without knowledge of the results of the (reference or other index) biopsies? Yes    
Were the MRI‐TBx performed independent of the (reference or other index) biopsies? Unclear    
Was the performance of the SBx not influenced by the performance of the (reference or other index) biopsies?      
    Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Was the reference standard performed independent from the index test? Yes    
    Low Low
DOMAIN 4: Flow and Timing
Did all patients receive the same reference standard? Yes    
Were all enrolled patients included in the analysis, or were exclusions explained and not leading to a relevant bias? Yes    
    Low